Filter By Category
Archives
Share on -
APADENOSON
Generic Name: APADENOSON
ABSTRACT -
Apadenoson is a selective adenosine A2A receptor agonist investigated for pharmacologic stress myocardial perfusion imaging.
It was designed to produce coronary vasodilation with fewer A1-, A2B-, and A3-mediated adverse effects than nonselective adenosine agonists.
It is not approved for routine clinical use.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- Clinical development evaluated intravenous bolus or infusion regimens for diagnostic stress testing.
- No approved standard dosing regimen is established.
- Administration requires cardiac monitoring and resuscitation capability similar to other pharmacologic stress agents.
SIDE EFFECTS–
- Possible side effects may include:
- Flushing
- Chest discomfort
- Dyspnea
- Headache
- Dizziness
- Nausea
- Hypotension or hypertension
- Atrioventricular block or arrhythmia
ALLRGIC REACTIONS–
- Hypersensitivity to the active compound or excipients is possible.
- Symptoms may include skin rash, urticaria, pruritus, facial swelling, wheezing, dizziness, or anaphylaxis.
- Patients with a suspected allergic reaction should stop treatment and seek urgent medical attention.
DRUG INTERACTIONS–
- Methylxanthines such as caffeine or theophylline can reduce adenosine-receptor agonist effects.
- Dipyridamole may enhance adenosine-type effects.
- Other vasoactive or rate-controlling drugs may alter hemodynamic response.
PREAUTIONS–
- Avoid in unstable angina, severe hypotension, decompensated heart failure, or severe conduction disease unless specifically allowed.
- Assess asthma or bronchospastic disease before use.
- Withhold caffeine/methylxanthines per imaging-protocol requirements.
- Monitor ECG, blood pressure, and symptoms during administration.
WARNINGS –
- Can provoke serious cardiac ischemia, arrhythmia, or bronchospasm in susceptible patients.
- Use only in monitored diagnostic settings.
- Not approved for routine clinical use.
Share on -
. Developed by